Virtus Fund Advisers’s Pacira BioSciences PCRX Stock Holding History

Virtus Fund Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-21,802	Closed	-$1.54M	–	857
2015 Q2	$1.54M	Sell	21,802 -303	-1%	-$23.9K	0.01%	332
2015 Q1	$1.96M	Buy	22,105 +3,072	+16%	+$312K	0.01%	320
2014 Q4	$1.69M	Buy	19,033 +92	+0.5%	+$8.7K	0.01%	347
2014 Q3	$1.84M	Sell	18,941 -2,910	-13%	-$283K	0.01%	348
2014 Q2	$2.01M	Buy	+21,851	New	+$1.66M	0.01%	365

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HCM

Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtus Fund Advisers's PCRX Position: Q3 2015 in Review

Virtus Fund Advisers sold out of Pacira BioSciences (PCRX) in Q3 2015, closing a stake of 21,802 shares — an estimated $1.54M sold.

Virtus Fund Advisers first reported a position in PCRX in Q2 2014 and held it in 5 quarters. The position peaked at $2.01M in Q2 2014. 177 funds tracked by Wall St. Rank hold PCRX as of Q3 2015.

Virtus Fund Advisers reported no remaining Pacira BioSciences position as of Q3 2015 after selling out during the quarter.
Virtus Fund Advisers sold 21,802 Pacira BioSciences shares in Q3 2015, an estimated $1.54M.
Virtus Fund Advisers first reported a position in Pacira BioSciences in Q2 2014 and held it in 5 quarters.
Virtus Fund Advisers's Pacira BioSciences position peaked at $2.01M in Q2 2014.
177 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2015.

Based on Virtus Fund Advisers's 13F filing for Q3 2015, filed 10 Nov 2015.